Source-grounded facts extracted from CV Sciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CV Sciences, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-06-02 meeting.
“Proposal 3 - Ratification of Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, as set forth below: FOR AGAINST ABSTAIN BROKER NON-VOTE 102,384,289 12,488,529 1,361,966 -”
CV Sciences, Inc. shareholders rejected Reverse Stock Split at the 2026-06-02 meeting.
“Proposal 2 - Reverse Stock Split The Company's stockholders did not approve the Company's proposal to amend its Certificate of Incorporation, as amended to effect, at the discretion of the Board of Directors, a reverse stock split of all outstanding shares of common stock at a ratio of not less than 1-for-10 and not greater than 1-for-800, such ratio to be determined by the Board of Directors at any time before May 30, 2029, without further approval or authorization from its stockholders, as set forth below: FOR AGAINST ABSTAIN BROKER NON-VOTE 48,496,747 59,628,926 8,109,111 -”
CV Sciences, Inc. shareholders approved Election of Directors at the 2026-06-02 meeting.
“Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject to prior death, resignation or removal, as set forth below: NAME FOR AGAINST ABSTAIN BROKER NON-VOTE Dr. Jamie Corroon 39,505,495 3,183,772 1,078,738 72,466,779 Joseph Dowling 37,674,977 4,813,319 1,279,709 72,466,779 Bill McCorkle 22,671,092 3,928,542 17,168,371 72,466,779”
CV Sciences, Inc. reported the quarter ended March 31, 2026 results: revenue $3.2 million.
“Generated revenue of $3.2 million for the first quarter 2026 compared to $3.6 million for the first quarter 2025”
CV Sciences, Inc. amended senior notes with the Investor maturing July 6, 2027.
“The April Amendment also extended the maturity date of the Third Note to July 6, 2027.”
CV Sciences, Inc. incurred senior notes of $99,614.04 with an institutional investor maturing April 6, 2027.
“On April 6, 2026, the Company issued the Investor a Third Note with a principal amount of $99,614.04.”
CV Sciences, Inc. entered into Third Note with the Investor valued at Principal amount $99,614.04, due April 6, 2027 (later extended) (effective 2026-04-06).
“disclosed, on February 12, 2025, CV Sciences, Inc., a Delaware corporation (the “Company”) entered into a note purchase agreement (the “Original Purchase Agreement”) with an institutional investor (“Investor”), pursuant to which the Company issued and sold to the Investor a secured promissory note in the original principal amount of $1,600,000 (the “Original Note”).”
CV Sciences, Inc. amended April Amendment with the Investor valued at Third Note principal amount $99,614.04; conversion price changed to $0.03 per share; maturity date o (effective 2026-04-09).
“On April 9, 2026, the Company and the Investor entered into an agreement (the "April Amendment") to amend the Notes to implement a new fixed conversion price equal to $0.03 per share.”
CV Sciences, Inc. reported the year and quarter ended December 31, 2025 results: revenue $13.8 million.
“its financial results for the year and quarter ended December 31, 2025. Fiscal 2025, Fourth Quarter 2025 and Recent Financial and Operating Highlights • Generated revenue of $13.8 million for fiscal 2025 compared to $15.7 million for 2024; Revenue of $3.3 million for the fourth quarter 2025 compared to $3.9 million for the fourth quarter 2024 and $3.3 million for”
CV Sciences, Inc. issued convertible note to institutional investor.
“the Company will issue a new senior secured convertible note on substantially the same terms and conditions of the Amended Notes (the “Third Note”) with a principal amount equal to the aggregate shortfall in excess of $94,000”
CV Sciences, Inc. issued convertible note to institutional investor for $2,256,000 aggregate outstanding principal amount.
“amounts of the Amended Notes were increased by 20% under the terms of the Notes. After such adjustment, the Amended Notes have an aggregate outstanding principal amount of $2,256,000. • True-Up Provision. The Amended Notes include a true-up provision designed to ensure that the net proceeds received by the Investor upon conversion and sale of the conversion”
CV Sciences, Inc. amended convertible notes of aggregate outstanding principal amount of $2,256,000 with institutional investor.
“amounts of the Amended Notes were increased by 20% under the terms of the Notes. After such adjustment, the Amended Notes have an aggregate outstanding principal amount of $2,256,000. • True-Up Provision. The Amended Notes include a true-up provision designed to ensure that the net proceeds received by the Investor upon conversion and sale of the conversion”
CV Sciences, Inc. amended Agreement with an institutional investor ("Investor") valued at aggregate outstanding principal amount of $2,256,000 (effective 2026-03-04).
“On March 4, 2026, the Company and the Investor entered into an agreement (the “Agreement”) to, among other things, amend and restate the Amended Original Note and the Second Note”
CV Sciences, Inc. entered into Membership Interest Purchase Agreement with Elevated Softgels, LLC, Clayton J. Montgomery, Chris Fagan, Andrew Kester, Timothy McGreer valued at Cash payment of $100,000; issuance of 15,854,185 restricted shares valued at $637,000; issuance of 1 (effective 2024-05-08).
“On May 8, 2024, CV Sciences, Inc. (the “Company”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) by and among the Company, Elevated Softgels, LLC, a Delaware limited liability company (“Elevated Softgels”), Clayton J. Montgomery (a “Member”), Chris Fagan, Andrew Kester, and Timothy McGreer, pursuant to which the Company purchased all of the outstanding equity interests in Elevated Softgels, resulting in Elevated Softgels becoming a wholly owned subsidiary of the Company (the “Acquisition”).”
CV Sciences, Inc. reported for the quarter ended March 31, 2024 results: revenue $4.0 million.
“and products, today announced its financial results for the quarter ended March 31, 2024. First Quarter 2024 and Recent Financial and Operating Highlights • Generated revenue of $4.0 million for first quarter 2024 compared to $4.1 million for the first quarter 2023 and a sequential improvement from $3.8 million for the fourth quarter 2023; • Recognized gross margin”
CV Sciences, Inc. reported the fourth quarter of 2023 results: revenue $3.8 million.
“Revenue of $3.8 million for the fourth quarter 2023 compared to $4.1 million in the third quarter 2023;”
CV Sciences, Inc. reported fiscal year ended December 31, 2023 results: revenue $16.0 million.
“Generated revenue of $16.0 million for fiscal 2023 compared to $16.2 million for 2022;”
CV Sciences, Inc. entered into Membership Interest Purchase Agreement with Cultured Foods Sp. z.o.o., Brian Carl McWhorter and Barbara McWhorter valued at cash payment of $175,000 to the Member, less a $17,500 holdback and ... an aggregate of 7,074,270 re (effective 2023-12-07).
“On December 7, 2023, CV Sciences, Inc. (the “Company”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) by and among the Company, Cultured Foods Sp. z.o.o., a limited liability company organized under the laws of Poland (“Cultured Foods”), Brian Carl McWhorter (the “Member”) and Barbara McWhorter, pursuant to which the Company purchased all of the outstanding equity interests in Cultured Foods, resulting in Cultured Foods becoming a wholly owned subsidiary of the Company (the “Acquisition”).”
CV Sciences, Inc. reported the quarter ended September 30, 2023 results: revenue $4.1 million.
“products, today announced its financial results for the quarter ended September 30, 2023. Third Quarter 2023 and Recent Financial and Operating Highlights • Increased revenue to $4.1 million for the third quarter 2023 compared to $3.8 million for third quarter 2022 and a sequential improvement from $4.0 million for the second quarter 2023; • Recognized gross margin”
CV Sciences, Inc. reported the quarter ended June 30, 2023 results: revenue $4.0 million.
“and products, today announced its financial results for the quarter ended June 30, 2023. Second Quarter 2023 and Recent Financial and Operating Highlights • Generated revenue of $4.0 million for the second quarter 2023 compared to $4.1 million for second quarter 2022; • Recognized gross margin of 43.3% for the second quarter 2023 compared to 30.7% for the second”
CV Sciences, Inc. shareholders approved Proposal 4 - Advisory Vote to Approve Named Executive Officer Compensation at the 2023-06-01 meeting.
“On June 1, 2023, the Company held the 2023 Annual Meeting in a virtual format. At the close of business on April 3, 2023, the record date for the 2023 Annual Meeting, there were 152,104,789 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company. At the 2023 Annual Meeting, 76,611,221 of the 152,104,789 outstanding shares of common stock entitled to vote, or approximately 50.4%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2023 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the 2023 Annual Meeting were as follows: Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject”
CV Sciences, Inc. shareholders approved Proposal 3 - Adoption of our 2023 Plan at the 2023-06-01 meeting.
“On June 1, 2023, the Company held the 2023 Annual Meeting in a virtual format. At the close of business on April 3, 2023, the record date for the 2023 Annual Meeting, there were 152,104,789 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company. At the 2023 Annual Meeting, 76,611,221 of the 152,104,789 outstanding shares of common stock entitled to vote, or approximately 50.4%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2023 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the 2023 Annual Meeting were as follows: Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject”
CV Sciences, Inc. shareholders approved Proposal 2 - Ratification of Selection of Independent Registered Public Accounting Firm at the 2023-06-01 meeting.
“On June 1, 2023, the Company held the 2023 Annual Meeting in a virtual format. At the close of business on April 3, 2023, the record date for the 2023 Annual Meeting, there were 152,104,789 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company. At the 2023 Annual Meeting, 76,611,221 of the 152,104,789 outstanding shares of common stock entitled to vote, or approximately 50.4%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2023 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the 2023 Annual Meeting were as follows: Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject”
CV Sciences, Inc. shareholders approved Proposal 1 - Election of Directors at the 2023-06-01 meeting.
“On June 1, 2023, the Company held the 2023 Annual Meeting in a virtual format. At the close of business on April 3, 2023, the record date for the 2023 Annual Meeting, there were 152,104,789 shares of common stock issued and outstanding, which constituted all of the outstanding capital stock of the Company. At the 2023 Annual Meeting, 76,611,221 of the 152,104,789 outstanding shares of common stock entitled to vote, or approximately 50.4%, were represented by proxy at the meeting, and, therefore, a quorum was present. The proposals voted on at the 2023 Annual Meeting are more fully described in Proxy Statement, which is incorporated herein by reference. The final voting results on the proposals presented for stockholder approval at the 2023 Annual Meeting were as follows: Proposal 1 - Election of Directors The Company's stockholders elected three directors, each to serve until the Company's next Annual Meeting of Stockholders or until his successor is duly elected and qualified, subject”
CV Sciences, Inc. reported the quarter ended March 31, 2023 results: revenue $4.1 million.
“CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2023. First Quarter 2023 and Recent Financial and Operating Highlights • Generated revenue of $4.1 million for the first quarter 2023 compared to $4.4 million for first quarter 2022 and a sequential increase of 7% from $3.9 million in the fourth quarter 2022;”
CV Sciences, Inc. reported the year and quarter ended December 31, 2022 results: revenue $16.2 million.
“its financial results for the year and quarter ended December 31, 2022. Fiscal 2022, Fourth Quarter 2022 and Recent Financial and Operating Highlights • Generated revenue of $16.2 million for fiscal year 2022 compared to $20.0 million for 2021; Revenue of $3.9 million for the fourth quarter 2022 sequential increase of 3% from $3.8 million in the third quarter”
CV Sciences, Inc. reported the quarter ended September 30, 2022 results: revenue $3.8 million.
“today announced its financial results for the quarter ended September 30, 2022. Third Quarter 2022 and Recent Financial and Operating Highlights • Revenue of $3.8 million for third quarter of 2022”
William McCorkle was appointed as Director at CV Sciences, Inc..
“On October 21, 2022, the Board of Directors of CV Sciences, Inc. (the "Company") appointed William McCorkle as a director on the Company’s Board of Directors (the “Board”).”
Dr. Joseph C. Maroon resigned as Director at CV Sciences, Inc..
“On July 21, 2022, Dr. Joseph C. Maroon resigned as a member of the Board of Directors of the Company.”
Dr. Jamie Corroon Jr. was appointed as Director at CV Sciences, Inc..
“On July 21, 2022, the Board of Directors of CV Sciences, Inc. (the "Company") appointed Dr. Jamie Corroon Jr., ND, MPH as a director on the Company’s Board of Directors (the “Board”).”
Douglas MacKay resigned as Senior Vice President, Scientific and Regulatory Affairs at CV Sciences, Inc..
“On September 24, 2021, Dr. Douglas MacKay submitted his resignation from his position as CV Sciences, Inc.'s Senior Vice President, Scientific and Regulatory Affairs.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.